FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:599-603 August 27, 1992 Number 9 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND AND METHODS. Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy. The patients were randomly assigned to receive either alternating one-month courses of methylprednisolone and then chlorambucil for a total of six months (group 1) or methylprednisolone alone for six months at the same cumulative dosage (group 2). RESULTS. Four of the 45 patients in group 1 (9 percent) and 1 of the 47 in group 2 (2 percent) stopped treatment because of side effects. At one, two, and three years, the percentage of patients who did not have the nephrotic syndrome was significantly higher in group 1 than in group 2. It was 58, 54, and 66 percent, respectively, in group 1, as compared with 26, 32, and 40 percent in group 2 (P = 0.002, 0.029, and 0.011). By year 4, the difference was no longer statistically significant: 62 percent of the patients in group 1 and 42 percent of those in group 2 did not have the nephrotic syndrome (P = 0.102). The patients in group 1 were in remission longer than those in group 2 (P = 0.008). CONCLUSIONS. In patients with the nephrotic syndrome caused by idiopathic membranous nephropathy, treatment with methylprednisolone and chlorambucil for six months induces an earlier remission of the nephrotic syndrome than methylprednisolone alone, but the difference may diminish with time.

Source Information

Division of Nephrology and Dialysis, Istituto Scientifico, Milan, Italy.

This article has been cited by other articles:

• Eriguchi, M., Oka, H., Mizobuchi, T., Kamimura, T., Sugawara, K., Harada, A. (2009). Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant 24: 3082-3088 [Abstract] [Full Text]  
• Bomback, A. S., Derebail, V. K., McGregor, J. G., Kshirsagar, A. V., Falk, R. J., Nachman, P. H. (2009). Rituximab Therapy for Membranous Nephropathy: A Systematic Review. CJASN 4: 734-744 [Abstract] [Full Text]  
• Fervenza, F. C., Sethi, S., Specks, U. (2008). Idiopathic Membranous Nephropathy: Diagnosis and Treatment. CJASN 3: 905-919 [Abstract] [Full Text]  
• Candiano, G., Musante, L., Bruschi, M., Petretto, A., Santucci, L., Boccio, P. D., Pavone, B., Perfumo, F., Urbani, A., Scolari, F., Ghiggeri, G. M. (2006). Repetitive Fragmentation Products of Albumin and {alpha}1-Antitrypsin in Glomerular Diseases Associated with Nephrotic Syndrome. J. Am. Soc. Nephrol. 17: 3139-3148 [Abstract] [Full Text]  
• Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G. B., Altieri, P., Ponticelli, C., Locatelli, F. (2004). Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial. J. Am. Soc. Nephrol. 15: 157-163 [Abstract] [Full Text]  
• Nachman, P. H., Martin, J. (2002). Developments in the Immunotherapy of Glomerular Disease. Journal of Pharmacy Practice 15: 472-489 [Abstract]  
• Ponticelli, C., Villa, M. (1999). Does cyclosporin have a role in the treatment of membranous nephropathy?. Nephrol Dial Transplant 14: 23-25  
• Lewis, E. J. (1993). Idiopathic Membranous Nephropathy -- To Treat or Not to Treat?. NEJM 329: 127-129 [Full Text]